Table 5

Performance of EBUS in the diagnosis of lung cancer across GM and comparison to national quality standards

Trust 1
four operators
Trust 2
four operators 2017
five operators 2018
Trust 3
one operator 2017
two operators 2018
Trust 4
seven operators
Trust 5
two operators
2017201820172018201720182017201820172018
Number of diagnostic EBUS9812226241182754811921
Pathological diagnosis91%96%80%91%98%93%93%91%94%95%
NSCLC-NOS rate3%
(4/154)
4%
(7/193)
25%
(11/44)
21%
(8/39)
2%
(4/214)
35%
(68/197)
7%
(8/113)
8%
(8/98)
17%
5/29
15%
4/27
Adequate tissue for EGFR91%
(89/98)
96%
(117/122)
55%
(12/22)
57%
(8/14)
99%
(93/94)
90%
(63/70)
90%
(55/61)
90%
35/39)
87%
13/15
94%
17/18
Adequate tissue for ALK98%
(96/98)
97%
(89/92)
64%
(16/22)
50%
(6/12)
100%
(30/30)
90%
(62/69)
90%
(51/57)
93%
37/40
80%
12/15
89%
16/18
  • EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; NSCLC, nonsmall cell lung cancer.